Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 18 , ISSUE 7 ( July, 2014 ) > List of Articles


Severe valproate induced hyperammonemic encephalopathy successfully managed with peritoneal dialysis

Amandeep Kumar, Ashish Suri, Bhawani S. Sharma

Keywords : Dialysis, valproate induce hyperammonemia, valproate induced hyperammonemic encephalopathy, valproic acid

Citation Information : Kumar A, Suri A, Sharma BS. Severe valproate induced hyperammonemic encephalopathy successfully managed with peritoneal dialysis. Indian J Crit Care Med 2014; 18 (7):461-463.

DOI: 10.4103/0972-5229.136076

License: CC BY-ND 3.0

Published Online: 01-10-2006

Copyright Statement:  Copyright © 2014; The Author(s).


Valproic acid (VPA) is a commonly used drug for epilepsy, psychiatric disorders and migraine and is frequently used in neurosurgical intensive care units. Though most of its side-effects are mild and transient, certain idiosyncratic side-effects have been attributed to VPA. Valproate induced hyperammonemia (VIH) is one such side-effect. VIH can produce symptoms of encephalopathy known as valproate induced hyperammonemic encephalopathy (VHE). VIH and VHE usually respond to withdrawal of VPA. However, in some cases VHE can be unresponsive to supportive measures and severe enough to be life-threatening. In such cases, dialysis can be used to rapidly reverse hyperammonemia and VHE and can prove to be a lifesaving measure. We report such a case of VIH and life-threatening VHE in a postoperative neurosurgical patient that was managed successfully with peritoneal dialysis.

PDF Share
  1. Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 1982;39:591-2.
  2. Mehndiratta MM, Mehndiratta P, Phul P, Garg S. Valproate induced non hepatic hyperammonaemic encephalopathy : A study from tertiary care referral university hospital, north India. J Pak Med Assoc 2008;58:627-31.
  3. Felipo V, Butterworth RF. Neurochemistry of ammonia. Neurochem Int 2002;41:79.
  4. Sewell AC, Böhles HJ, Herwig J, Demirkol M. Neurological deterioration in patients with urea cycle disorders under valproate therapy: A cause for concern. Eur J Pediatr 1995;154:593-4.
  5. Ott CA, Campbell N, Dworek EA. Valproic acid-induced hyperammonemia in a patient with schizoaffective disorder. J Pharm Pract 2007;20:82-92.
  6. Prietsch V, Lindner M, Zschocke J, Nyhan WL, Hoffmann GF. Emergency management of inherited metabolic diseases. J Inherit Metab Dis 2002;25:531-46.
  7. Bohan TP, Helton E, McDonald I, König S, Gazitt S, Sugimoto T, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56:1405-9.
  8. Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning. Clin Toxicol (Phila) 2009;47:609-16.
  9. Tsai MF, Chen CY. Valproate-induced hyperammonemic encephalopathy treated by hemodialysis. Ren Fail 2008;30:822-4.
  10. Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T. Acute valproate poisoning: Pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 2005;25:376-80.
  11. Nasa P, Sehrawat D, Kansal S, Chawla R. Effectiveness of hemodialysis in a case of severe valproate overdose. Indian J Crit Care Med 2011;15:120-2.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.